<DOC>
	<DOCNO>NCT01336829</DOCNO>
	<brief_summary>The purpose study see effect etravirine TMC278 telaprevir absorb body effect telaprevir etravirine TMC278 absorb body administer together .</brief_summary>
	<brief_title>TMC125IFD1001 - Drug-Drug Interaction Etravirine With Telaprevir TMC278 With Telaprevir .</brief_title>
	<detailed_description>This open-label , randomize , single-dose , crossover trial healthy volunteer . Crossover mean participant may receive different intervention sequentially trial . Randomized mean assign treatment sequence chance , like flip coin . Open-label mean physician know treatment receive . The study consist 3 phase : screening phase , treatment phase follow-up phase . Total study duration individual participant approximately 11 week . Once find eligible screening phase , participant take part one two part treatment phase . In first part , group 16 participant receive two treatment session , A B . The order treatment give determine chance . In treatment A , 200 mg ( 2 tablet ) ETR ( etravirine ) give twice day day 1 10 morning dose day 11 . In treatment B , 750 mg ( 2 tablet ) TVR ( telaprevir ) give day 1 17 every 8 hour morning afternoon dose day 18 200 mg ETR give twice day day 8 17 morning dose day 18 . In 2 session , least 14 day . In second part , another group 16 participant receive 2 treatment session , C D. The order treatment give determine chance . In treatment C , 25 mg ( 1 tablet ) TMC278 give day day 1 11 . In treatment D , 750 mg ( 2 tablet ) TVR ( telaprevir ) give day 1 18 every 8 hour 25 mg TMC278 give day day 8 18 . In 2 session , least 14 day . All treatment take food . In treatment A C , participants come unit day dose morning day 1 , 9 10 whole day day 11 . Only treatment C , overnight stay day 11 day 12 foreseen . In treatment B , participants come unit day dose morning day 1 , 5 , 6 , 8 , 16 17 whole day day 7 18 . In treatment D , participants come unit day dose morning day 1 , 5 , 6 , 8 , 12 , 16 17 whole day day 7 18 overnight stay day 18 19 . Five 7 day last dosing , participant last follow-up visit unit ( follow-up phase ) . During study , safety monitor , treatment phase , specify timepoints , blood sample take pharmacokinetic evalutions ( effect body drug ) . In treatment A , 2 tablet ETR give twice day day 1 10 morning dose day 11 . In treatment B , 2 tablet TVR give every 8 hour day 1 to17 2 dos day 18 2 tablet ETR twice day day 8 17 morning dose day 18 . In treatment C , 1 tablet TMC278 give oncy day day 1 11 . In treatment D , 2 tablet TVR give every 8 hour day 1 18 1 tablet TMC278 day day 8 18 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection A Body Mass Index ( BMI , weight kg divide square height meter ) 18.5 30.0 kg/m2 Healthy basis physical examination , medical history , vital sign , electrocardiogram clinical laboratory test perform Screening Women must postmenopausal least 2 year surgically sterile heterosexually active duration study , vasectomized partner , childbearing potential heterosexually active , practice highly effective method birth control . History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise participant 's safety and/or compliance study procedures A positive urine drug test Screening Use disallow therapy : concomitant medication , include overthecounter product , herbal preparation dietary supplement History significant drug allergy Received investigational drug use investigational medical device within 60 day precede first intake study medication previously participate study either ETR , TMC278 , telaprevir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HIV</keyword>
	<keyword>TMC125IFD1001</keyword>
	<keyword>TMC125</keyword>
	<keyword>Intelence</keyword>
	<keyword>etravirine</keyword>
	<keyword>ETR</keyword>
	<keyword>TMC278</keyword>
	<keyword>telaprevir</keyword>
	<keyword>TVR</keyword>
	<keyword>VX-950</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>crossover</keyword>
</DOC>